BML Capital Management, LLC - Q3 2023 holdings

$109 Million is the total value of BML Capital Management, LLC's 26 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 57.1% .

 Value Shares↓ Weighting
ADVM SellADVERUM BIOTECHNOLOGIES INC$5,872,500
-28.4%
3,915,000
-24.1%
5.39%
-26.9%
ATHA SellATHIRA PHARMA INC$3,442,811
-37.4%
1,704,362
-8.6%
3.16%
-36.1%
ORMP SellORAMED PHARMACEUTICALS INC$2,039,172
-33.0%
781,292
-8.1%
1.87%
-31.6%
SellENLIVEN THERAPEUTICS INC$683,000
-54.9%
50,000
-32.6%
0.63%
-54.0%
RVP SellRETRACTABLE TECHNOLOGIES INC$594,951
-22.6%
499,959
-25.2%
0.55%
-21.1%
SellSURROZEN INC$43,743
-94.5%
89,271
-93.9%
0.04%
-94.5%
NLTX ExitNEOLEUKIN THERAPEUTICS INC$0-23,749
-100.0%
-0.02%
ExitINVIVYD INC$0-134,696
-100.0%
-0.13%
ExitMEI PHARMA INC$0-22,966
-100.0%
-0.14%
GRPH ExitGRAPHITE BIO INC$0-152,291
-100.0%
-0.36%
TLYS ExitTILLYS INCcl a$0-190,518
-100.0%
-1.20%
CRTX ExitQUINCE THERAPEUTICS INC$0-1,411,839
-100.0%
-1.91%
ANF ExitABERCROMBIE & FITCH COcl a$0-117,500
-100.0%
-3.98%
ExitPARDES BIOSCIENCES INC$0-3,791,633
-100.0%
-6.17%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-10-23
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
SPDR SER TR4Q3 202316.9%
ADVERUM BIOTECHNOLOGIES INC4Q3 20237.4%
ELIEM THERAPEUTICS INC4Q3 20236.4%
ATHIRA PHARMA INC4Q3 20234.9%
ASTROTECH CORP4Q3 20232.8%
ARCA BIOPHARMA INC4Q3 20231.9%
FORTE BIOSCIENCES INC4Q3 20231.6%
VERRICA PHARMACEUTICALS INC4Q3 20232.9%
PASSAGE BIO INC4Q3 20231.7%
RETRACTABLE TECHNOLOGIES INC4Q3 20231.0%

View BML Capital Management, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR/A2024-04-24
13F-HR2024-04-23
13F-HR/A2024-02-02
13F-HR2024-01-30
13F-HR2023-10-23
13F-HR2023-07-24
13F-HR2023-04-14
13F-HR2023-02-13

View BML Capital Management, LLC's complete filings history.

Export BML Capital Management, LLC's holdings